Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI
NCT04272242Phase 2Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of dolutegravir in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Started Feb 2021; status: terminated.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04272242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04272242.